Results overview: Found 2 records in 0.02 seconds.
Articles, 2 records found
Articles 2 records found  
1.
12 p, 942.4 KB BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer / Karachaliou, Niki (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Codony-Servat, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ; Teixidó, Cristina (Pangaea Biotech (Barcelona, Catalunya)) ; Pilotto, Sara (University of Verona (Itàlia)) ; Drozdowskyj, Ana (Pivotal (Madrid)) ; Codony-Servat, Carles (Pangaea Biotech (Barcelona, Catalunya)) ; Giménez-Capitán, Ana (Pangaea Biotech (Barcelona, Catalunya)) ; Molina-Vila, Miguel Ángel (Pangaea Biotech (Barcelona, Catalunya)) ; Bertrán-Alamillo, Jordi (Pangaea Biotech (Barcelona, Catalunya)) ; Gervais, Radj (Centre François Baclesse (Caen, França)) ; Massuti, Bartomeu (Hospital General de Alicante) ; Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Majem, Margarita (Hospital de Sant Pau (Barcelona, Catalunya)) ; Felip Font, Enriqueta (Hospital Vall d'Hebron (Barcelona, Catalunya)) ; Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ; Viteri, Santiago (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; González-Cao, María (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Morales-Espinosa, Daniela (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Verlicchi, Alberto (Ospedale Santa Maria delle Croci (Ravenna, Itàlia)) ; Crisetti, Elisabetta (Institute of Respiratory Diseases. University of Foggia (Itàlia)) ; Chaib, Imane (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Santarpia, Mariacarmela (Human Pathology Department. University of Messina (Itàlia)) ; Ramírez, José Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Bosch-Barrera, Joaquim (Hospital Josep Trueta, Girona. Institut Català d'Oncologia) ; Cardona Zorrilla, Andrés Felipe (Instituto de Oncología de Clínica del Country (Bogotá, Colòmbia)) ; De Marinis, Filippo (Istituto Europeo di Oncologia (Milà, Itàlia)) ; López-Vivanco, Guillermo (Hospital de Cruces (Barakaldo, Biscaia)) ; Sánchez, José Miguel (Hospital Universitario de la Princesa (Madrid)) ; Vergnenegre, Alain (Hôpital du Cluzeau (Limoges, França)) ; Sánchez Hernández, José Javier (Universidad Autónoma de Nuevo León (Mèxic)) ; Sperduti, Isabella (Istituto Regina Elena Cancer Institute (Roma, Itàlia)) ; Bria, Emilio (University of Verona (Itàlia)) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Abstract. BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates apoptosis and may influence response to EGFR TKI. We examined mRNA expression of BIM and MTOR in 57 patients with EGFR-mutant NSCLC from the EURTAC trial. [...]
2015 - 10.1038/srep17499
Scientific reports, Vol. 7 (December 2015)  
2.
9 p, 2.1 MB ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability / Scheffler, Matthias (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya)) ; Schultheis, Anne (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya)) ; Teixidó, Cristina (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Michels, Sebastian (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya)) ; Morales Espinosa, Daniela (Institut Germans Trias i Pujol) ; Viteri, Santiago (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Hartmann, Wolfgang (University Hospital of Münster (Alemanya)) ; Merkelbach Bruse, Sabine (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya)) ; Fischer, Rieke (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya)) ; Schildhaus, Hans Ulrich (University Medical Center of Göttingen (Alemanya)) ; Fassunke, Jana (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya)) ; Sebastian, Martin (University Hospital of Frankfurt (Alemanya)) ; Serke, Monika (Lung Clinic Hemer (Alemanya)) ; Kaminsky, Britta (Bethanien Hospital (Solingen, Alemanya)) ; Randerath, Winfried (Bethanien Hospital (Solingen, Alemanya)) ; Gerigk, Ulrich (Malteser Hospital Seliger Gerhard Bonn/Rhein-Sieg (Alemanya)) ; Ko, Yon Dschun (Johanniter Hospital (Bonn, Alemanya)) ; Krüger, Stefan (Florence-Nightingale Hospital (Düsseldorf, Alemanya)) ; Schnell, Roland ; Rothe, Achim ; Kropf Sanchen, Cornelia (University Hospital Ulm (Alemanya)) ; Heukamp, Lukas (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya)) ; Rosell, Rafael (Hospital Universitari Quiron Dexeus (Barcelona, Catalunya)) ; Büttner, Reinhard (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya)) ; Wolf, Jürgen (Center for Integrated Oncology Köln Bonn (Cologne, Alemanya))
BACKGROUND: While recent data show that crizotinib is highly effective in patients with ROS1 rearrangement, few data is available about the prognostic impact, the predictive value for different treatments, and the genetic heterogeneity of ROS1-positive patients. [...]
2015 - 10.18632/oncotarget.3387
Oncotarget, Vol. 6 Núm. 12 (april 2015)  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.